Characterization of novel small non-coding RNAs and their modifications in bladder cancer using an updated small RNA-seq workflow

Abstract

Background: Bladder cancer (BLCA) is one of the most common cancer types worldwide. The disease is responsible for about 200,000 deaths annually, thus improved diagnostics and therapy is needed. A large body of evidence reveal that small RNAs of less than 40 nucleotides may act as tumor suppressors, oncogenes, and disease biomarkers, with a major focus on microRNAs. However, the role of other families of small RNAs is not yet deciphered. Recent results suggest that small RNAs and their modification status, play a role in BLCA development and are promising biomarkers due to their high abundance in the exomes and body fluids (including urine). Moreover, free modified nucleosides have been detected at elevated levels from the urine of BLCA patients. A genome-wide view of small RNAs, and their modifications, will help pinpoint the molecules that could be used as biomarker or has important biology in BLCA development.Methods: BLCA tumor tissue specimens were obtained from 12 patients undergoing transurethral resection of non-muscle invasive papillary urothelial carcinomas. Genome-wide profiling of small RNAs less than 40 bases long was performed by a modified protocol with TGIRT (thermostable group II reverse transcriptase) to identify novel small RNAs and their modification status.Results: Comprehensive analysis identified not only microRNAs. Intriguingly, 57 ± 15% (mean ± S.D.) of sequencing reads mapped to non-microRNA-small RNAs including tRNA-derived fragments (tRFs), ribosomal RNA-derived fragments (rRFs) and YRNA-derived fragments (YRFs). Misincorporation (mismatch) sites identified potential base modification positions on the small RNAs, especially on tRFs, corresponding to m1A (N1-methyladenosine), m1G (N1-methylguanosine) and m22G (N2, N2-dimethylguanosine). We also detected mismatch sites on rRFs corresponding to known modifications on 28 and 18S rRNA.Conclusion: We found abundant non-microRNA-small RNAs in BLCA tumor samples. Small RNAs, especially tRFs and rRFs, contain modifications that can be captured as mismatch by TGIRT sequencing. Both the modifications and the non-microRNA-small RNAs should be explored as a biomarker for BLCA detection or follow-up.

A Novel tiRNA-Gly-GCC-1 Promotes Progression of Urothelial Bladder Carcinoma and Directly Targets TLR4

“…They found that the expression of 5′-TRF-LySCtt in UBC tissue was positively correlated with the progression rate of UBC (multivariate Cox: HR = 2.368; p -value = 0.033) and negatively correlated with the prognosis of patients (multivariate Cox: HR = 2.151; p -value = 0.032) [ 21 ]. Another study found abundant tsRNAs in UBC which contained modifications that can be captured as a mismatch by TGIRT sequencing [ 22 ]. Lastly, TRMT6/61A-dependent base methylation of tsRNAs was stated to regμLate gene-silencing activity and the unfolded protein response in UBC [ 23 ].…”

Small RNA modifications: regulatory molecules and potential applications

“…Recently, with the rapid development of detection techniques, the great potential of small RNA modification as a biomarker of disease is being realized. For example, Su and workers used an improved RNA sequencing detection technique of Thermostable Group II Intron Reverse Transcriptase (TGIRT) and discovered the presence of m1A, m1G and N2, N2- dimethylguanosine (m 2 2 G) modifications on tsRNAs and rsRNAs in bladder cancer cells [ 180 ]. Yan and colleagues applied a highly efficient liquid chromatography-tandem mass spectrometry method and discovered that small RNA modifications in the liver cells of diabetic mice were significantly altered compared to control treatment, highlighting the correlation between small RNA modifications and diabetes [ 181 ].…”

tRNA-Derived Fragments as Biomarkers in Bladder Cancer

“…Relatively little is known about the role of tRF in BC pathogenesis, though Su et al identified a specific tRF methylation pattern in BC cells that attenuated gene silencing of potential proto-oncogenes. tRFs with specific methylation patterns may thus be drivers of oncogenesis in BC [15][16][17].…”